Emergent BioSolutions (NYSE: EBS) announced that it has partnered with the British Columbia (B.C.) Provincial Health Services Authority (PHSA) to supply NARCAN Nasal Spray for the province’s Take-Home Naloxone Program (BC THN Program).
According to Emergent, the order follows an additional investment of $18 million by the B.C. government to expand the BC THN Program to include nasal naloxone. This is an expansion of B.C.’s nasal naloxone pilot program, which launched in 2024.
In a statement, Paul Williams, senior vice president, head of products business, global government and public affairs at Emergent, commented, “We applaud the B.C. Ministry of Health for their efforts to make nasal naloxone available to communities across B.C. and empower more people to be ready to save a life in the event of an opioid poisoning. We are proud to deliver products to help protect and save lives through our footprint in Canada with over 300 employees across Emergent’s Winnipeg, Manitoba manufacturing facility and offices in Mississauga, Ontario.”
